Advertisement
Singapore markets close in 4 hours 38 minutes

  • Straits Times Index

    3,283.25
    -9.88 (-0.30%)
     

  • Nikkei

    37,711.70
    -748.38 (-1.95%)
     

  • Hang Seng

    17,295.93
    +94.66 (+0.55%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,149.96
    -2,537.20 (-3.80%)
     

  • CMC Crypto 200

    1,388.50
    -35.60 (-2.50%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,326.10
    -12.30 (-0.53%)
     

  • Crude Oil

    82.87
    +0.06 (+0.07%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,569.95
    -1.53 (-0.10%)
     

  • Jakarta Composite Index

    7,151.41
    -23.12 (-0.32%)
     

  • PSE Index

    6,580.26
    +7.51 (+0.11%)
     

Endo’s Generic and International Segments Declined in Q1 2018

Kenneth Smith
Updated
Endo’s Generic and International Segments Declined in Q1 2018

Under Endo International’s (ENDP) established products, Percocet sales increased from $30.94 million in Q1 2017 to $31.97 million in Q1 2018. The increase was attributable to higher prices, partially offset by a decline in volume. Voltaren gel sales, on the other hand, decreased from $14.27 million in Q1 2017 to $11.32 million in Q1 2018 due to lower prices resulting from generic competition. Sales from other established products also decreased, from $64.48 million in Q1 2017 to $45.03 million in Q1 2018.

Continue reading